Publication:
CBA (4-chloro-2-(2-chlorophenoxy)acetamido) benzoic acid) inhibits TMEM206 mediated currents and TMEM206 does not contribute to acid-induced cell death in colorectal cancer cells

cris.virtual.author-orcid0009-0006-4376-7959
cris.virtual.author-orcid0000-0003-4930-1886
cris.virtualsource.author-orcida76d6b99-eb7a-42b8-9e78-8a5b78c76aed
cris.virtualsource.author-orcid505afc62-d641-464b-a8e0-5ad727ed9d82
cris.virtualsource.author-orcidab0421a7-802d-4df5-adc1-edf735f69143
cris.virtualsource.author-orcide5e2ea05-f556-4f8d-a2cd-7db4c65dd364
cris.virtualsource.author-orcid902f94f2-f23b-485b-b431-b84c91df0d19
cris.virtualsource.author-orcid8ecd9cb4-6581-4dbe-9f46-87443cd81f0c
cris.virtualsource.author-orcid89e49780-414b-4f63-a9ef-037fb28a32b2
dc.contributor.authorKappel, Sven
dc.contributor.authorMelek, Korollus
dc.contributor.authorRoss-Kaschitza, Daniela
dc.contributor.authorHauert, Barbara
dc.contributor.authorGerber, Christian Elias
dc.contributor.authorLochner, Martin
dc.contributor.authorPeinelt, Christine
dc.date.accessioned2024-10-26T17:31:36Z
dc.date.available2024-10-26T17:31:36Z
dc.date.issued2024-03-07
dc.description.abstractIntroduction: Upon activation at low pH, TMEM206 conducts Cl− ions across plasma and vesicular membranes. In a (patho)physiological context, TMEM206 was reported to contribute to acid-induced cell death in neurons, kidney and cervical epithelial cells. We investigated the role of TMEM206 in acidinduced cell death in colorectal cancer cells. In addition, we studied CBA as a new small molecule inhibitor for TMEM206. Methods: The role of TMEM206 in acid-induced cell death was studied with CRISPR/Cas9-mediated knockout and FACS analysis. The pharmacology of TMEM206 was determined with the patch clamp technique. Results: In colorectal cancer cells, TMEM206 is not a critical mediator of acidinduced cell death. CBA is a small molecule inhibitor of TMEM206 (IC50 = 9.55 μM) at low pH, at pH 6.0 inhibition is limited. Conclusion: CBA demonstrates effective and specific inhibition of TMEM206; however, its inhibitory efficacy is limited at pH 6.0. Despite this limitation, CBA is a potent inhibitor for functional studies at pH 4.5 and may be a promising scaffold for the development of future TMEM206 inhibitors.
dc.description.numberOfPages9
dc.description.sponsorshipInstitut für Biochemie und Molekulare Medizin (IBMM)
dc.identifier.doi10.48350/194042
dc.identifier.pmid38515848
dc.identifier.publisherDOI10.3389/fphar.2024.1369513
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/175354
dc.language.isoen
dc.publisherFrontiers
dc.relation.ispartofFrontiers in Pharmacology
dc.relation.issn1663-9812
dc.relation.organizationDCD5A442BCD9E17DE0405C82790C4DE2
dc.relation.schoolDCD5A442C27BE17DE0405C82790C4DE2
dc.subject.ddc500 - Science::570 - Life sciences; biology
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.subject.ddc500 - Science::540 - Chemistry
dc.titleCBA (4-chloro-2-(2-chlorophenoxy)acetamido) benzoic acid) inhibits TMEM206 mediated currents and TMEM206 does not contribute to acid-induced cell death in colorectal cancer cells
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.volume15
oairecerif.author.affiliationInstitut für Biochemie und Molekulare Medizin (IBMM)
oairecerif.author.affiliationInstitut für Biochemie und Molekulare Medizin (IBMM)
oairecerif.author.affiliationInstitut für Biochemie und Molekulare Medizin (IBMM)
oairecerif.author.affiliationInstitut für Biochemie und Molekulare Medizin (IBMM)
oairecerif.author.affiliationInstitut für Biochemie und Molekulare Medizin (IBMM)
oairecerif.author.affiliationInstitut für Biochemie und Molekulare Medizin (IBMM)
oairecerif.author.affiliationInstitut für Biochemie und Molekulare Medizin (IBMM)
oairecerif.author.affiliation2IBMM Gruppe Peinelt
oairecerif.author.affiliation2IBMM Gruppe Peinelt
oairecerif.author.affiliation2IBMM Gruppe Peinelt
oairecerif.author.affiliation2IBMM Gruppe Peinelt
oairecerif.author.affiliation2IBMM Gruppe Lochner
oairecerif.author.affiliation2IBMM Gruppe Lochner
oairecerif.author.affiliation2IBMM Gruppe Peinelt
oairecerif.identifier.urlhttps://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1369513/full
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2024-03-08 09:48:15
unibe.description.ispublishedpub
unibe.eprints.legacyId194042
unibe.refereedTRUE
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
2024_Kappel_Front_Pharmacol.pdf
Size:
1.92 MB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by/4.0
Content:
published

Collections